Vanguard Asset Management
JANX icon

Vanguard Asset Management’s Janux Therapeutics JANX Stock Holding History

Vanguard Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$375K Hold
24,439
– – ﹤0.01% 2293
2026
Q1 		$340K Buy
+24,439
New +$335K ﹤0.01% 2259

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Asset Management's JANX Position: Q2 2026 in Review

Vanguard Asset Management held its Janux Therapeutics (JANX) position steady in Q2 2026 at 24,439 shares worth $375K. The position accounts for ﹤0.01% of the portfolio, ranked #2293.

Vanguard Asset Management first reported a position in JANX in Q1 2026 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Vanguard Asset Management held 24,439 shares of Janux Therapeutics worth $375K as of Q2 2026.
  • Vanguard Asset Management left its Janux Therapeutics share count unchanged in Q2 2026.
  • Janux Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2293 holding.
  • Vanguard Asset Management first reported a position in Janux Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.